根据健之佳医药连锁集团股份有限公司（以下简称"公司"）2025年第一次临时股东会审议通过的《关于 取消监事会、设置职工董事并修订〈公司章程〉及附件的议案》，根据法律法规的规定及公司实际，拟 调整公司治理架构，同时变更经营范围，对《公司章程》的相关内容进行修订和完善，办理工商变更登 记。具体内容详见公司于2025年8月29日在上海证券交易所网站（www.sse.com.cn）披露的《关于取消 监事会、设置职工董事并修订〈公司章程〉及附件的公告》（公告编号：2025-046） 近日，公司完成了增加经营范围的工商变更登记及修订《公司章程》的工商备案手续，并取得云南省市 场监督管理局换发的《营业执照》。 证券代码：605266 证券简称：健之佳 公告编号：2025-053 健之佳医药连锁集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 《营业执照》中除经营范围外的其余登记内容未变更。 特此公告。 健之佳医药连锁集团股份有限公司董事会 2025年10月11日 《营业执照》变更登记 ...

转载请注明来源：柠檬兄弟公关 "有人说五仁不好吃，那是因为你还年轻，还没饱尝过生活的毒打"。2025年9月，某知名食品企业的这条电梯广告一经发布，迅速引发舆论哗然。 买个月饼为何要遭受"生活的毒打"？消费者纷纷质疑这条广告的"说教"意味和"PUA式营销"手法。 在舆论压力下，该企业不得不在广告上线一天后迅速将其下架并公开道歉。 01 营销翻车：多元案例与问题凸显 某食品企业的"毒打论"并非孤例。2025年上半年，某乳业品牌因一系列地铁广告被推上风口浪尖。 其"COWS直聘，找工作，直接跟老板哞"及"跳槽吧！奶牛，听说你们场晒不到太阳？"等广告语，被指嘲讽打工人生存状态，引发广泛争议。 某科技巨头也在广告创意上频频受挫。据媒体报道，约一年时间内，该公司已下架4次"争议性"广告。 其中包括去年5月的《Crush!》广告——一台液压机压毁钢琴、唱片机等创作工具，最后露出新款平板电脑，被批评为"对人类创造力的亵渎"。 清明营销失误同样引人深思。某汽车品牌在2025年清明节期间，推出宣传85度电池的海报，标语为"清明换电随时走"。 这种将传统节日沉重氛围与产品轻松语调结合的做法，被指缺乏对文化的尊重。 纵观这些翻车案例 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-051 健之佳医药连锁集团股份有限公司 关于公司非独立董事辞任、选举职工董事及 一、非独立董事辞任情况 公司董事会2025年9月17日收到非独立董事李恒先生递交的《关于辞任公司董事的报告》。因公司治理 架构调整及个人工作规划，李恒先生辞任公司第六届董事会非独立董事。根据《中华人民共和国公司 法》及相关法律法规，《公司章程》、《董事和高级管理人员离职管理制度》等有关规定，李恒先生的 辞任报告自2025年9月17日送达公司时生效，其辞任不会导致公司董事会成员低于法定最低人数。 辞任后李恒先生担任公司副总经理、董事会秘书、财务总监职务。 二、选举职工董事情况 根据《公司章程》，公司设职工董事1名，由公司职工代表大会民主选举产生。 2025年9月17日，公司职工代表大会选举金玉梅女士（简历附后）为公司第六届董事会职工董事，任期 至第六届董事会任期届满之日止。 三、选举董事会薪酬与考核委员会委员情况 选举职工董事为董事会薪酬与考核委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-049 健之佳医药连锁集团股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月17日 (二)股东大会召开的地点：云南省昆明市盘龙区联盟街道旗营街10号健之佳总部14楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 1、公司在任董事7人，出席6人，本次会议独立董事陈方若先生因会议时间冲突，未能出席会议； 2、公司在任监事3人，出席3人； 3、董事会秘书李恒先生出席本次会议； 4、总经理蓝波先生、副总经理李恒先生列席本次会议。 二、议案审议情况 (一)非累积投票议案 本次临时股东会由公司董事会召集，公司董事长蓝波先生主持，本次股东会的召集、召开及表决方式符 合《中华人民共和国公司法》等法律、法规及规范性文件及《 ...

Core Viewpoint - The current industry consolidation window is evident, with small and medium-sized chain enterprises facing multiple pressures from new social security regulations, strong supervision from medical insurance and taxation, creating favorable conditions for consolidation [1] Group 1: Company Strategy - The company management prefers a prudent consolidation strategy based on strategic layout, focusing on developing chain franchise business and comprehensive terminal procurement membership business to build a more competitive business model [1] - The company plans to strengthen regional markets through small-scale acquisitions in already entered markets rather than pursuing large-scale expansion [1] - In the short term, the company will adopt a cautious approach to seize consolidation opportunities while continuously monitoring market dynamics to lay the foundation for higher quality consolidation and layout in the future [1]

Group 1 - The board of directors of Jianzhijia Pharmaceutical Chain Group Co., Ltd. held its 12th meeting of the 6th session on August 28, 2025, with all 7 directors present and voting [1] - The board approved a proposal to cancel the supervisory board, establish employee directors, and amend the company's articles of association, which will be submitted for shareholder approval [2][3] - The company aims to improve its governance structure and operational norms by adding and revising several internal regulations, including a new "Management System for Departing Directors and Senior Management" and revisions to the "Audit Committee Work Guidelines" among 12 other documents [2]

Group 1 - The company held its ninth meeting of the sixth supervisory board on August 28, 2025, with all three supervisors present, complying with relevant laws and regulations [1] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report, with a unanimous vote of 3 in favor and no opposition or abstentions [1][2] - The supervisory board confirmed that the preparation and review process of the 2025 semi-annual report adhered to legal and regulatory requirements, ensuring the information is true, accurate, and complete [2] Group 2 - The supervisory board also approved a proposal to cancel the supervisory board, establish employee directors, and amend the company's articles of association, which will be submitted to the shareholders' meeting for review [2]

Meeting Overview - The company will hold a shareholder meeting on September 17, 2025, at 14:30 in Kunming, Yunnan Province [1] - The meeting will utilize a combination of on-site and online voting methods [1] - The online voting system will be available from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, either via trading terminal or internet platform [2] - Shareholders with multiple accounts can aggregate their voting rights across all accounts [3] - Duplicate votes through different methods will be counted based on the first vote cast [3] Attendance Requirements - Only shareholders registered by the close of business on September 10, 2025, are eligible to attend the meeting [4] - Shareholders must complete registration in advance to ensure smooth proceedings [4] Proxy Voting - Shareholders can appoint a proxy to attend and vote on their behalf, with specific documentation required for both natural and legal persons [4][5] - The proxy must indicate their voting intention on the proxy form [7]

Core Viewpoint - The company, Jianzhijia Pharmaceutical Chain Group Co., Ltd., will hold a half-year performance briefing on August 29, 2025, to discuss its operational and financial status for the first half of 2025, addressing common investor concerns [2][3][4]. Group 1: Meeting Details - The performance briefing is scheduled for August 29, 2025, from 10:00 AM to 11:00 AM [4][6]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [6][5]. - Participants will include the company's Chairman and General Manager, Mr. Lan Bo, the Secretary of the Board and Chief Financial Officer, Mr. Li Heng, and Independent Director, Mr. Guan Yunhong [4]. Group 2: Investor Participation - Investors can participate in the briefing online via the Shanghai Stock Exchange Roadshow Center on the scheduled date [5][6]. - Investors are encouraged to submit questions from August 22 to August 28, 2025, through the Roadshow Center's website or via the company's email [5][6]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Contact Information - For inquiries, investors can contact Mr. Li Heng at phone number 0871-65711920 or via email at ir@jzj.cn [7]. - After the briefing, the main content and details will be available on the Shanghai Stock Exchange Roadshow Center [7].

Group 1 - The company will hold a half-year performance briefing on August 29, 2025, from 10:00 to 11:00 AM [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Key personnel attending the briefing include the Chairman and General Manager, Mr. Lan Bo, the Secretary of the Board and CFO, Mr. Li Heng, and the Independent Director, Mr. Guan Yunhong [2] Group 2 - Investors can submit questions for the briefing from August 22, 2025, to August 28, 2025, by visiting the Roadshow Center website or emailing the company [3] - During the briefing, the company will address common concerns from investors regarding its operational performance and financial status for the first half of 2025 [2][3] - After the briefing, investors can access the main content and details of the event through the Roadshow Center [3]